Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Two Doses of ALIMTA (Pemetrexed) as First Line Chemotherapy for Advanced Breast Cancer

NCT00065533 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00065533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00065533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Two Doses of ALIMTA (Pemetrexed) as First Line Chemotherapy for Advanced Breast Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2003
Completion date
June 30, 2005
Enrollment
92 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer